The consequence of chronic high blood pressure is increasingly prevalence of chronic kidney disease (CKD) and cardiovascular organ injury, prevalence the high costs and poor outcomes of treatment are a significant health issue at clinical. In this study, hypothesis the Kefir-fermented product derived from milk protein (as a nature source) with the protection of the kidney function in management of salt-induced chronic kidney disease. Therefore, we used the salt-induced kidney disease in stroke-prone spontaneously hypertensive rats (SHRSP) as an animal model. SHRSP rats at 50–60 weeks of age were orally administered kefir-derived peptides (KDP) for four weeks. The results of KDP have good performance of anti- hypertension effect, further studies of immunohistochemical staining and western blotting showed that salt-induced kidney failure significantly increased the protein levels of CD68, MCP-1, α-SMA and ET-1 under 1% NaCl drinking water induction. However, treatment with KDP significantly decreased macrophage infiltration marker CD68, MCP-1, α-SMA and ET-1 levels compared to those in mock group of salt-treated SHRSP rats (P<0.05). Moreover, the results demonstrated that KDP improved salt-induced impaired kidney function. The examination of kidney histopathology further showed that KDP administration significantly decreased salt-induced glomerulosclerosis, tubular damage, collagen deposition, interlobular arterial thickness (P<0.05). These conclusion suggested that KDP exerted potent protection against salt-induced chronic kidney disease and antihypertension in SHRSP rats. Therefore, kefir-derived peptides may represent a novel kidney protective agent in clinical use.
Date:
2017-04
Relation:
The FASEB Journal. 2017 Apr;31(1, Suppl.):Meeting Abstract 855.12.
